tiprankstipranks
Sutro Biopharma Inc (STRO)
NASDAQ:STRO

Sutro Biopharma Stock Analysis & Ratings

STRO Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$3.33 - $23.70
Previous Close$4.33
Volume16.99M
Average Volume (3M)576.73K
Market CapN/A
Enterprise ValueN/A
P/E Ratio-1.8
Beta1.90
Next EarningsAug 10, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score7


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

STRO FAQ

What was Sutro Biopharma’s price range in the past 12 months?
Sutro Biopharma lowest stock price was $3.33 and its highest was $23.70 in the past 12 months.
    What is Sutro Biopharma’s market cap?
    Currently, no data Available
    What is Sutro Biopharma’s price target?
    The average price target for Sutro Biopharma is $26.67. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
    The highest analyst price target is $30.00 ,the lowest forecast is $20.00. The average price target represents 409.94% Increase from the current price of $5.23.
      What do analysts say about Sutro Biopharma?
      Sutro Biopharma’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
        When is Sutro Biopharma’s upcoming earnings report date?
        Sutro Biopharma’s upcoming earnings report date is Aug 10, 2022 which is in 42 days.
          How were Sutro Biopharma’s earnings last quarter?
          Sutro Biopharma released its earnings results on May 09, 2022. The company reported -$0.84 earnings per share for the quarter, missing the consensus estimate of -$0.757 by -$0.083.
            Is Sutro Biopharma overvalued?
            According to Wall Street analysts Sutro Biopharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
              Does Sutro Biopharma pay dividends?
              Sutro Biopharma does not currently pay dividends.
              What is Sutro Biopharma’s EPS estimate?
              Sutro Biopharma’s EPS estimate is -$0.66.
                How many shares outstanding does Sutro Biopharma have?
                Sutro Biopharma has 46,934,113 shares outstanding.
                  What happened to Sutro Biopharma’s price movement after its last earnings report?
                  Sutro Biopharma reported an EPS of -$0.84 in its last earnings report, missing expectations of -$0.757. Following the earnings report the stock price went up 5.964%.
                    Which hedge fund is a major shareholder of Sutro Biopharma?
                    Among the largest hedge funds holding Sutro Biopharma’s share is Driehaus Capital Management LLC. It holds Sutro Biopharma’s shares valued at N/A.

                      ---

                      Sutro Biopharma Stock Analysis

                      The Sutro Biopharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Sutro Biopharma Inc

                      Sutro Biopharma Inc. engages in the drug discovery, development and manufacturing of pharmaceutical products. Its products technologies include XpressCF, anti-body drug conjugates, bispecifics & engineered antibodies and cGMP facility. The company was founded by James R. Swartz and Sutanto Widjaja in June 2003 and is headquartered in South San Francisco, CA.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Y-Mabs Therapeutics
                      Replimune Group
                      Gritstone Oncology

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis